The safety and efficacy of monoclonal antibody therapy with low-dose bamlanivimab plus etesevimab was similar to that of higher doses of the drug combination in patients with mild to moderate COVID-19 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback